The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
A phase 3 trial of FAP-2286, Enzalutamide, Abiraterone acetate in prostate cancer, run by Telix Pharmaceuticals (Innovations) Pty Limited, now recruiting.
Overview
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) is a phase 3 interventional study registered as NCT06520345 by Telix Pharmaceuticals (Innovations) Pty Limited, with 520 participants planned, started 2024-07-26 and due to reach its primary completion in 2027-12. Interventions recorded: 177Lu-TLX591, Enzalutamide, Abiraterone, Docetaxel. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Shares Enzalutamide, Abiraterone acetate, Docetaxel, Prostate cancer.
- TrialAn Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc
Shares Enzalutamide, Abiraterone acetate, Prostate cancer.
- TrialStudy of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Shares Enzalutamide, Abiraterone acetate, Docetaxel, Prostate cancer.
- TrialAnti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Shares FAP-2286 (177Lu / 68Ga), Prostate cancer.
- TrialPSMA PET Combined With MRI for the Detection of PCa
Shares Telix Pharmaceuticals, Prostate cancer.
- TrialA Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA
Shares Enzalutamide, Abiraterone acetate, Prostate cancer.
- TrialAbiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Shares Enzalutamide, Abiraterone acetate, Prostate cancer.
- TrialAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Shares FAP-2286 (177Lu / 68Ga), Prostate cancer.